With the best-selling medication in the world, tirzepatide, and a record-setting $1 trillion valuation to go with it, Eli ...

Amid an outpouring of obesity data Monday, Wave Life Sciences and Structure Therapeutics were among the biotechs jockeying to ...

A closer look at phase 3 data on BioNTech and OncoC4’s anti-CTLA-4 antibody has shown the efficacy that excited analysts last ...

The Chinese biotech evaluated three different once-daily doses of its oral GLP-1 agonist, dubbed ASC30, in a phase 2 study of ...

Stryker, with its eye on tuck-in acquisitions and streamlining its business core, has promoted 27-year veteran Spencer Stiles ...

Close to two years after AbbVie handed over $48 million for the rights to OSE Immunotherapeutics’ inflammation drug, the Big ...

Resmed believes its artificial intelligence-powered approach to personalizing the settings of its connected CPAP machines can lead to better sleep for people with obstructive apnea. | Resmed believes ...

Nine years after Sarepta Therapeutics’ Exondys 51 won a controversial FDA approval to treat a subset of patients with Duchenne muscular dystrophy, challenger from Massachusetts biotech Dyne ...

Mirum Pharmaceuticals is paying $620 million in cash and stock to buy Bluejay Therapeutics and its phase 3-stage hepatitis drug. At the heart of the deal is brelovitug, an immunoglobulin G1 monoclonal ...

In rodents, Amphista linked its BRD9 degrader AMX-883 to a significant improvement in survival and reduction in disease burden compared to Venclexta. Combining AMX-883 with Venclexta and azacitidine ...

AGC Biologics is sounding the alarm on a projected “microbial manufacturing crunch” as demand for large-scale fermentation capacity sharply increases. | AGC Biologics’ Dieter Kramer shares insights, d ...

With dosing underway in a pivotal phase 3 trial, Star Therapeutics is illuminating the clinical potential of its ...